SNF Refusal of Buprenorphine Can Delay Discharge for Patients With OUD

A perspective in the Journal of General Internal Medicine describes a patient with opioid use disorder whose skilled-nursing facility initially refused readmission after he began buprenorphine. The case highlights persistent knowledge and stigma barriers despite removal of the federal X-waiver requirement and outlines advocacy approaches for hospital teams.

SNF refusal extended this patient’s hospitalization by about a month.
Federal X-waiver requirements ended in January 2023.
Hospital-facility discussions enabled discharge on buprenorphine.
The article is a perspective centered on one case.

The perspective presents the case of a 50-year-old man with cirrhosis, chronic pain and severe opioid use disorder who was hospitalized with hepatic encephalopathy. After treatment, he transitioned from fentanyl and oxycodone to buprenorphine/naloxone 16 mg/4 mg sublingually daily, with pain and opioid use disorder controlled and encephalopathy resolved. His skilled-nursing facility initially refused to readmit him because he was taking buprenorphine, extending his hospitalization by about a month.

The authors explain that the facility’s concern about its physician’s authority to prescribe reflected a misunderstanding: the federal X-waiver requirement was eliminated in January 2023, and inpatient clinicians were not required to hold one to dispense or administer buprenorphine. The hospital team held clinician-to-clinician discussions with the facility, which ultimately accepted the patient on treatment.

The authors describe facility refusals of patients receiving medication for opioid use disorder as a continuing barrier associated with delayed discharge and rehabilitation, and note that refusing care on this basis may violate the Americans with Disabilities Act. They recommend clinician education, mentorship and institutional advocacy. This is a perspective built around one case, not a comparative study; its broader claims draw on cited literature. State-level prescribing restrictions and resource pressures at skilled-nursing facilities may also affect access.

In practice

For hospitalized patients with opioid use disorder who are stabilized on buprenorphine, this case supports addressing facility concerns through direct communication rather than automatically interrupting treatment to secure placement. The authors note that inpatient clinicians do not need an X-waiver to dispense or administer buprenorphine, and that federal waiver requirements for prescribing ended in January 2023. The account is a single case within a perspective, not comparative evidence; local rules and individual clinical circumstances still matter, and it does not establish how commonly advocacy resolves refusals.

AI-generated clinical interpretation · Not editor-reviewed

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Source

Journal of General Internal Medicine: Discriminatory Practice in Opioid Use Disorder: In a Post-X-Waiver Era, Barriers to Buprenorphine Persist ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.